Batoclimab
- Generic Name
- Batoclimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2187430-05-1
- Unique Ingredient Identifier
- C98V9UMX3D
- Background
Batoclimab is under investigation in clinical trial NCT04428255 (A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP).
- Associated Conditions
- -
- Associated Therapies
- -
Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses
Immunovant reported positive results from a trial investigating batoclimab in Graves’ disease patients, with a 76% response rate. The company also plans a pivotal trial for IMVT-1402 by year-end, targeting Graves’ disease. Batoclimab showed a 56% ATD-Free Response and is also being evaluated for thyroid eye disease and CIDP.
Related Clinical Trials:
Immunovant Provides Update on Graves' Disease Development Program
High dose batoclimab achieved 76% response rate and 56% ATD-Free response rate in Graves’ Disease patients uncontrolled on antithyroid drugs at week 12. A strong correlation between IgG lowering and clinical outcomes suggests potential best-in-class status for IMVT-1402. An IND has been cleared, with a pivotal trial expected by year-end.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath